4LA van Es.IgA Nephropathy.In:Shaul G.Massry Richard J.Glassock.Massary & Massock's textbook of nephrology.4th.Lippincott Williams & Wilkins,2001,733-735.
2Paolo TS,Marco G,Francesco DC. Continuing follow- up of malignant hypertension. J Nephrol, 2002,15 (4) : 431 - 437.
3Lip G, Beevers M,Beevers G. The failure of malignant hypertension to decline: a survey of 24 years' experience in a multiracial population in England. J Hypertens, 1994, 12(11): 1297- 1305.
4Kitiyakara C, Guzman NJ. Malignant hypertension and hypertensive emergencies. J Am Soc Nephro, 1998,9 ( 1 ): 133- 142.
5Joint National Committee for the Detection, Evaluation and Treatment of High Blood Pressure: the 1984 report. Arch Intern Med, 1984,114(5): 1045 - 1057.
6Guidelines Committee. 2003 European Society of Hypertension- European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens, 2003,21(6) :1011 - 1053.
7Subias R,Botey A, Darnell A. Malignant or accelerated hypertension in IgA nephropathy. Clin Nephrol, 1987,27:1
8Glassock RJ. IgA nephropathy(Berger' s disease). In Brenner BM & Rector Fc(eds) :The Kidney,ed 2, vol 2, pp1400 -1405, Saunders, London, 1981.
9Lens XM, Montoliu J,Aubias R, et al. Malignant essential hypertension: comparison with malignant hypertension in IgA nephropathy (Abstract). Kidney Int, 1985,28(1) :250.
10Fleming S. Malignant hypertension- the role of the paracrine renin- angiotensin system. J Pathol, 2000,192 ( 2 ): 135 - 139.
